Impacting Cancer

Nextech Invest, October 2017
Is this email not displaying correctly?
View it in your browser.

Dear Reader, 

Thanks to a technological revolution that is transforming the industry, novel cancer therapies are being developed faster, more efficiently and with far greater efficacy than ever before. We are pleased to announce that Jakob Loven, PhD, has joined Nextech as Partner at this time of great promise for patients and opportunity for investors.

CAR-T cell therapies have dominated the news in recent weeks with the USD 12 billion acquisition of Kite Pharma by Gilead and two FDA approvals of Kymriah and Yescarta. In this edition of Impacting Cancer, we share perspectives on both the science and business of CAR-T cell therapies. We hope you enjoy reading about our recent investment in Autolus, a leading CAR-T cell company and a featured interview with Autolus CEO Christian Itin, PhD. You will also find an article written by Jakob Loven, PhD, and Kristina Beeler, PhD, on CAR-Ts and a video featuring Nextech Scientific Board member and immunotherapy luminary Philip D. Greenberg, MD, providing more insight into this exciting field.

With kind regards, 
Your Nextech Team

Nextech News

Nextech welcomes Jakob Loven as Partner

We are proud to announce that Jakob Loven, PhD, (third from left) has joined Nextech Invest as Partner. Jakob Loven is an accomplished oncology-focused entrepreneur and life science venture capitalist with extensive experience in creating, launching and building early stage therapeutic oncology companies. Prior to joining Nextech, Jakob worked at ThirdRock Ventures in Boston, MA, where he co-founded Relay Therapeutics. Jakob was the scientific founder of Syros Pharmaceuticals [SYRS], which is based on foundational technology and intellectual property he invented during his postdoctoral fellowship at the Whitehead Institute/Massachusetts Institute of Technology, Cambridge, MA.

Read the press release.

Nextech Insights

CAR-T cells in oncology

In this edition of Nextech Insights, Jakob Loven, PhD, Partner, and Kristina Beeler, PhD, Principal, take a closer look at recent developments in the immuno-oncology industry with a focus on CAR-Ts.

Read the article.

Interview

Engineering patients' immune cells

In this Nextech exclusive interview, Christian Itin, PhD, CEO of Autolus, talks about how Autolus is engineering patients' proper immune cells to combat cancer and the first wave on cell based therapies that were recently approved by the FDA. 

Read the interview

Portfolio News

Nextech Invest welcomes Autolus to the portfolio

Autolus, a London based oncology company specialized on the programming and manufacturing of CAR-T cells has announced the closing of a USD 80 million Series C financing. Nextech Invest joined Cormorant Asset Management and others as new investors along existing investors Syncona Ltd, Woodford Investment Management and Arix Bioscience in this financing.

Read the press release.

 

Video

Philip D. Greenberg, MD, member of the Nextech Scientific Board, provides insight about the opportunity in immuno-oncology.

Kura Oncology [KURA] announced the positive outcome of a clinical Phase 2 study for tipifarnib in HRAS mutant head and neck cancer.

Read the press release.

Blueprint Medicines [BPMC] announced new data from an ongoing Phase 1 clinical trial of BLU-554 in patients with advanced hepatocellular carcinoma.

Read the press release.

ImaginAb closed a USD 8 million new funding to accelerate the clinical development of a CD8 ImmunoPET agent for monitoring anti-tumor activity of the immune system.

Read the press release

ImaginAb announced a strategic collaboration with Boehringer Ingelheim to develop new technology for monitoring anti-tumor activity of the immune system.

Read the press release

Autolus announced the completion of the first-dose cohort in the APRIL Study of AUTO2: a clinical Phase 1/2 study in patients with multiple myeloma.

Read the press release.

Autolus announced the initiation of the AMELIA and ALEXANDER studies for AUTO3: Phase 1/2 studies in pediatric acute lymphoblastic leukemia and diffuse large B cell lymphoma.

Read the press release.

Tracon Pharmaceuticals [TCON] announced the completion of patient enrollment in the randomized clinical Phase 2b TRAXAR study of TRC105 and Inlyta® in renal cell carcinoma.

Read the press release

Impressum
Nextech Invest Ltd.
Turnerstrasse 26
8006 Zurich, Switzerland

Web: www.nextechinvest.com
E-Mail: info@nextechinvest.com